全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Overview of Adrenals Tumors in Dakar Hospitals

DOI: 10.4236/ojim.2024.142013, PP. 141-150

Keywords: Tumour, Adrenal, Pheochromocytoma, Conn, Adrenocortical Carcinoma, Dakar

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: Adrenal tumours (AT) are commonly encountered in clinical practice. For any patient presenting an adrenal mass, there are two crucial points to consider: is the adrenal mass malignant and is it hormonally active? The objective of our study was to evaluate the epidemiological, diagnostic, therapeutic, and evolutionary aspects of AT in a developing country. Methodology: We conducted a retrospective study spanning 17 years (from January 2005 to October 2022) in four Dakar hospital services. We included all patient medical records with explored AT. Results: AT was diagnosed in 35 patients who had a mean age of 36.62 years (range: 12-79), and a female predominance (26 women to 9 men). Among these patients, 17.2 % had incidental AT. Hypertension was the commonest presenting symptom in 27 patients (77%), which was associated with Ménard’s triad in 14 patients (40%). Abdominal pain was reported by 20 patients (57%), and 14 presented with an abdominal mass. Among the patients, 29 had functional AT: 22 with pheochromocytoma, 5 with primary hyperaldosteronism, and 2 with hypercortisolism. Imaging evaluations revealed that 33 patients had unilateral AT and one had bilateral AT. Tumour sizes varied, 5 patients had tumours <4 cm, 20 patients had tumours between 4 and 10 cm, and 10 patients had tumours >10 cm. Two patients presented with metastases. The therapeutic approach involved adrenalectomy in 32 patients. Perioperative complications were observed in five patients, including haemorrhage (two patients), hypotension (two cases), and hypertensive crisis (one case). One patient with bilateral pheochromocytoma developed acute adrenal insufficiency postoperatively, followed by abdominal herniation. Histopathological examination confirmed pheochromocytoma in 21 patients, Conn’s adenoma in 5, adrenocortical carcinoma in 3, cortisol adenoma in 2, and adrenal cyst in 1 patient. Non-functional AT included adrenocortical carcinoma (three patients), adrenal cyst (one patient), and pheochromocytoma (two patients). After a one-year follow-up, 29 patients with benign tumours had favourable outcomes, while death occurred within six months of diagnosis in five cases. A patient who had bilateral pheochromocytomas, with complications, died before surgery. Conclusion: In our practice, AT are predominantly pheochromocytomas, being typically diagnosed when they become symptomatic large tumours and, due to

References

[1]  Ebbehoj, A., Li, D., Kaur, R.J., Zhang, C., Singh, S., Li, T., et al. (2020) Epidemiology of Adrenal Tumours in Olmsted County, Minnesota, USA: A Population-Based Cohort Study. The Lancet Diabetes & Endocrinology, 8, 894-902.
https://doi.org/10.1016/S2213-8587(20)30314-4
[2]  (2002) NIH State-of-the-Science Statement on Management of the Clinically Inapparent Adrenal Mass (“Incidentaloma”). NIH Consensus and State-of-the-Science Statements, 19, 1-25.
[3]  Pinto, A. and Barletta, J.A. (2015) Adrenal Tumors in Adults. Surgical Pathology, 8, 725-749.
https://doi.org/10.1016/j.path.2015.07.005
[4]  Almeida, M.Q., Bezerra-Neto, J.E., Mendonça, B.B., Latronico, A.C. and Fragoso, M.C. (2018) Primary Malignant Tumors of the Adrenal Glands. Clinics, 73, e756s.
[5]  Lam, A.K. (2017) Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocrine Pathology, 28, 213-227.
https://doi.org/10.1007/s12022-017-9484-5
[6]  Yalniz, C., Morani, A.C., Waguespack, S.G. and Elsayes, K.M. (2020) Imaging of Adrenal-Related Endocrine Disorders. Radiologic Clinics of North America, 58, 1099-1113.
https://doi.org/10.1016/j.rcl.2020.07.010
[7]  Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., Arlt, W. and Dekkers, O.M. (2023) European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenal Incidentalomas, in Collaboration with the European Network for the Study of Adrenal Tumors. European Journal of Endocrinology, 189, G1-G42.
https://doi.org/10.1093/ejendo/lvad066
[8]  Yang, Y., Reinck, M. and Williams, T.A. (2020) Prevalence, Diagnosis and Outcomes of Treatment for Primary Aldosteronism. Best Practice & Research Clinical Endocrinology & Metabolism, 34, Article 101365.
https://doi.org/10.1016/j.beem.2019.101365
[9]  Rimoldi, S.F., Sherrer, U. and Messerli, F.H. (2014) Secondary Arterial Hypertension: When, Who and How to Screen. European Heart Journal, 35, 1245-1254.
https://doi.org/10.1093/eurheartj/eht534
[10]  Sbardella, E. and Grossman, A.B. (2020) Pheochromocytoma, an Approach to Diagnosis. Best Practice & Research Clinical Endocrinology & Metabolism, 34, Article 101346.
https://doi.org/10.1016/j.beem.2019.101346
[11]  Leye, A., Pouye, A., Fall, B., et al. (2003) Pheochromocytoma in Dakar: About 9 Observations. Dakar Medical, 48, 77-81.
[12]  Huddle, K.R.L. (2011) Phaeochromocytoma in Black South Africans—A 30-Year Audit. South African Medical Journal, 101, 184-188.
https://doi.org/10.7196/SAMJ.4320
[13]  Leye, A., Ndiaye, N., Leye, Y.M., Cisse, A.F., Diack, N.D., Ndour, M.A., Dieng, A., Thioub, D., Kane, B.S., Bahati, A., Touré, A.O., Dial, C.M. and Diop, P.S. (2018) Management of Pheochromocytoma in Dakar: Diagnostic and Therapeutic Advances throughout 16 Cases. Open Journal of Endocrine and Metabolic Diseases, 8, 19-28.
https://doi.org/10.4236/ojemd.2018.81003
[14]  Savoie, P.H., Murez, T., Flechon, A., Rocher, L., Ferretti, L., Morel-Journel, N., et al. (2020) French ccAFU Guidelines—Update 2020-2022: Malignancy Assessment of an Adrenal Incidentaloma. Progrés En Urologie, 30, S331-S352.
https://doi.org/10.1016/S1166-7087(20)30756-9
[15]  Mayo-Smith, W.W., Song, J.H., Boland, G.L., Francis, I.R., Israel, G.M., Mazzaglia, P.J., et al. (2017) Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee. Journal of the American College of Radiology, 14, 1038-1044.
https://doi.org/10.1016/j.jacr.2017.05.001
[16]  Jasim, S. and Jimenez, C. (2020) Metastatic Pheochromocytoma and Paraganglioma: Management of Endocrine Manifestations, Surgery and Ablative Procedures, and Systemic Therapies. Best Practice & Research Clinical Endocrinology & Metabolism, 34, Article 101354.
https://doi.org/10.1016/j.beem.2019.101354
[17]  Gupta, G. and Pacak, K. (2017) AACE Adrenal Scientific Committee. Precision Medicine: An Update on Genotype/Biochemical Phenotype Relationships in Pheochromocytoma/Paraganglioma Patients. Endocrine Practice, 23, 690-704.
https://doi.org/10.4158/EP161718.RA
[18]  Castinetti, F., Qi, X.P., Walz, M.K., Maia, A.L., Sansó, G., Peczkowska, M., et al. (2014) Outcomes of Adrenal-Sparing Surgery or Total Adrenalectomy in Phaeochromocytoma Associated with Multiple Endocrine Neoplasia Type 2: An International Retrospective Population-Based Study. The Lancet Oncology, 15, 648-655.
https://doi.org/10.1016/S1470-2045(14)70154-8
[19]  Dhir, M., Li, W., Hogg, M.E., et al. (2017) Clinical Predictors of Malignancy in Patients with Pheochromocytoma and Paraganglioma. Annals of Surgical Oncology, 24, 3624-3630.
https://doi.org/10.1245/s10434-017-6074-1

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133